← All trials
NCT06130072
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 10, 2023
- Primary completion
- Mar 10, 2024
- Completion date
- Mar 10, 2024
- First posted
- Nov 13, 2023
- Last posted
- Nov 13, 2023
- Enrollment
- 45
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ain Shams UniversityLead sponsor
- Ain Shams UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.